Use of immunotherapy in the treatment of gastric cancer (Review)
- Authors:
- Luhong Yang
- Yanxia Wang
- Huafeng Wang
-
Affiliations: Modern College of Humanities and Science, Shanxi Normal University, Linfen, Shanxi 041004, P.R. China, School of Life Science, Shanxi Normal University, Linfen, Shanxi 041004, P.R. China - Published online on: September 30, 2019 https://doi.org/10.3892/ol.2019.10935
- Pages: 5681-5690
-
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Takeuchi C, Yamamichi N, Shimamoto T, Takahashi Y, Mitsushima T and Koike K: Gastric polyps diagnosed by double-contrast upper gastrointestinal barium X-ray radiography mostly arise from the Helicobacter pylori-negative stomach with low risk of gastric cancer in Japan. Gastric Cancer. 20:314–321. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu G, Torres J, Hu N, Medrano-Guzman R, Herrera-Goepfert R, Humphrys MS, Wang L, Wang C, Ding T, Ravel J, et al: Molecular characterization of the human stomach microbiota in gastric cancer patients. Front Cell Infect Microbiol. 7:3022017. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shen L, Xu JM, Feng FY, Jiao SC, Wang LW, Li J, Guan ZZ, Qin SK, Wang JJ, Yu SY, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: A Phase III, multi-center, randomized controlled trial, Chinese subreport. Zhonghua Zhong Liu Za Zhi. 35:295–300. 2013.(In Chinese). PubMed/NCBI | |
|
Galdy S, Cella CA, Spada F, Murgioni S, Frezza AM, Ravenda SP, Zampino MG and Fazio N: Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. Crit Rev Oncol Hematol. 99:1–12. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mellman I: Immunotherapies definition. Dictionary.com. Retrieved 2009-06-02. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Masihi KN: Fighting infection using immunomodulatory agents. Expert Opin Biol Ther. 1:641–653. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Copp J, Xie WD, Zhang C and Berglin J: Immunotherapy and cell therapy for cancer. CJPT. 30:87–94. 2016. | |
|
Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science. 342:1432–1433. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Douglas H and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Walker LS: Treg and CTLA-4: Two intertwining pathways to immune tolerance. J Autoimmun. 45:49–57. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dolan DE and Gupta S: PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy. Cancer Control. 21:231–237. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jacob JA: Cancer immunotherapy researchers focus on refining checkpoint blockade therapies. JAMA. 314:2117–2119. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ipilimumab, . https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm | |
|
Hellmann MD, Ott PA, Zugazagoitia J, Ready NE, Hann CL, De Braud FG, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, et al: Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 35:85032017. View Article : Google Scholar | |
|
ClinicalTrials.gov, . An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy. https://clinicaltrials.gov/ct2/show/NCT01585987 | |
|
Tremelimumab, . https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm | |
|
Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, Hawkins RE and Thistlethwaite FC: Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 16:1662–1672. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Scapin G, Yang X, Prosise WW, McCoy M, Reichert P, Johnston JM, Kashi RS and Strickland C: Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 22:953–958. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, et al: Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: Results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 22:828–837. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
ClinicalTrials.gov, . A study of pembrolizumab (MK-3475) in participants with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (MK-3475-059/KEYNOTE-059). https://clinicaltrials.gov/ct2/show/NCT02335411 | |
|
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet. 392:123–133. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
ClinicalTrials.gov, . A study of pembrolizumab (MK-3475) versus paclitaxel for participants with advanced gastric/gastroesophageal junction adenocarcinoma that progressed after therapy with platinum and fluoropyrimidine (MK-3475-061/KEYNOTE-061). https://clinicaltrials.gov/ct2/show/NCT02370498 | |
|
ClinicalTrials.gov, . Study of pembrolizumab (MK-3475) as first-line monotherapy and combination therapy for treatment of advanced gastric or gastroesophageal junction adenocarcinoma (MK-3475-062/KEYNOTE-062). https://clinicaltrials.gov/ct2/show/NCT02494583 | |
|
Nivolumab, . https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm | |
|
Le TD, Bendell JC, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Bono P, Jeffry D, Evans TRJ, et al: Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. J Clin Oncol. 34:2016. View Article : Google Scholar | |
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Boku N, Kang YK, Satoh T, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yoshikawa T, et al: 617OA Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol. 28:2017. View Article : Google Scholar : PubMed/NCBI | |
|
ClinicalTrials.gov, . A study of nivolumab by itself or nivolumab combined with ipilimumab in patients with advanced or metastatic solid tumors. https://clinicaltrials.gov/ct2/show/NCT01928394 | |
|
Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, et al: Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 7:133542016. View Article : Google Scholar : PubMed/NCBI | |
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Vasselli XL, Ibrahim RA, Lutzky J and Khleif S: Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol. 32:30022014. View Article : Google Scholar | |
|
Levy A, Massard C, Soria JC and Deutsch E: Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 68:156–162. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
A phase 1b/2 study of MEDI4736 with tremelimumab, MEDI4736 or tremelimumab monotherapy in gastric or GEJ adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT02340975 | |
|
Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, et al: Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 7:302019. View Article : Google Scholar : PubMed/NCBI | |
|
ClinicalTrials.gov, . Avelumab in metastatic or locally advanced solid tumors (JAVELIN Solid Tumor JPN). https://clinicaltrials.gov/ct2/show/NCT01943461 | |
|
Mohme M, Riethdorf S and Pantel K: Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 14:155–167. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stauss HJ, Morris EC and Abken H: Cancer gene therapy with T cell receptors and chimeric antigen receptors. Curr Opin Pharmacol. 24:113–118. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Patel JM, Dale GA, Vartabedian VF, Dey P and Selvaraj P: Cancer CARtography: Charting out a new approach to cancer immunotherapy. Immunotherapy. 6:675–678. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gill S, Maus MV and Porter DL: Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 30:157–167. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Zhang Z, Peng M, Fu S, Xue Z and Zhang R: CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside. Oncoimmunology. 5:e12515392016. View Article : Google Scholar : PubMed/NCBI | |
|
Novartis CAR-T cell therapy CTL019 receives FDA breakthrough therapy designation for treatment of adult patients with r/r DLBCL. https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation | |
|
Lee YH and Kim CH: Evolution of chimeric antigen receptor (CAR) T cell therapy: Current status and future perspectives. Arch Pharm Res. Mar 4–2019.(Epub ahead of print). View Article : Google Scholar | |
|
Brudno JN and Kochenderfer JN: Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 34:45–55. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH and Sherwin SA: Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 5:222017. View Article : Google Scholar : PubMed/NCBI | |
|
Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, et al: Study protocol for THINK: A multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 7:e0170752017. View Article : Google Scholar : PubMed/NCBI | |
|
Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, et al: Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res. 5:1152–1161. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, et al: Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther. 25:1248–1258. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Li W, Huang K, Zhang Y, Kupfer G and Zhao Q: Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward. J Hematol Oncol. 11:222018. View Article : Google Scholar : PubMed/NCBI | |
|
Abrahao-Machado LF and Scapulatempo-Neto C: HER2 testing in gastric cancer: An update. World J Gastroenterol. 22:4619–4625. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, et al: Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 18:691–697. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB and Schaeffer DF: HER2/neu testing in gastric cancer by immunohistochemistry: Assessment of interlaboratory variation. Arch Pathol Lab Med. 138:1495–1502. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zulfiqar M, Bhalla A, Weindel M and Shidham VB: Molecular diagnostics in esophageal and gastric neoplasms. Clin Lab Med. 33:867–873. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Whilding LM and Maher J: ErbB-targeted CAR T-cell immunotherapy of cancer. Immunotherapy. 7:229–241. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
A clinical research of CAR T cells targeting HER2 positive cancer. https://clinicaltrials.gov/ct2/show/NCT02713984 | |
|
ClinicalTrials.gov, . Treatment of chemotherapy refractory human epidermalgrowth factor receptor-2(HER-2) positive advanced solid tumors (CART-HER-2). https://clinicaltrials.gov/ct2/show/NCT01935843 | |
|
ClinicalTrials.gov, . Her2 and TGFBeta cytotoxic T cells in treatment of Her2 positive malignancy (HERCREEM). https://clinicaltrials.gov/ct2/show/NCT00889954 | |
|
Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, Mineno J, Takesako K, Kato T and Shiku H: Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology. 5:e12112182016. View Article : Google Scholar : PubMed/NCBI | |
|
Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kühlcke K, et al: Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother. 63:133–145. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, et al: MUC1-ARF-A novel MUC1 protein that resides in the nucleus and is expressed by alternate reading frame translation of MUC1 mRNA. PLoS One. 11:e01650312016. View Article : Google Scholar : PubMed/NCBI | |
|
Rajabi H, Hiraki M, Tagde A, Alam M, Bouillez A, Christensen CL, Samur M, Wong KK and Kufe D: MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep. 7:74812017. View Article : Google Scholar : PubMed/NCBI | |
|
Genitsch V, Zlobec I, Thalmann GN and Fleischmann A: MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor. Prostate Cancer Prostatic Dis. 19:242–247. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HK, Kwon MJ, Seo J, Kim JW, Hong M, Park HR, Min SK, Choe JY, Ra YJ, Jang SH, et al: Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer. Pathol Res Pract. 215:459–465. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang MH, Sun R, Zhou XM, Zhang MY, Lu JB, Yang Y, Zeng LS, Yang XZ, Shi L, Xiao RW, et al: Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway. Cell Death Dis. 9:22018. View Article : Google Scholar : PubMed/NCBI | |
|
Maher J and Wilkie S: CAR mechanics: Driving T cells into the MUC of cancer. Cancer Res. 69:4559–4562. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Warneke VS, Behrens HM, Haag J, Krüger S, Simon E, Mathiak M, Ebert MP and Röcken C: Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. Br J Cancer. 109:2217–2227. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
ClinicalTrials.gov, . CAR-T cell immunotherapy in MUC1 positive solid tumor. https://clinicaltrials.gov/ct2/show/NCT02617134 | |
|
ClinicalTrials.gov, . Study evaluating the efficacy and safety with CAR-T for stomach cancer (EECSC). https://clinicaltrials.gov/ct2/show/NCT02725125 | |
|
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheever MA and Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 17:3520–3526. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ribas A, Butterfield LH, Glaspy JA and Economou JS: Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 21:2415–2432. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gilliam AD and Watson SA: G17DT: An antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 7:397–404. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Park DJ, Thomas NJ, Yoon C and Yoon SS: Vascular endothelial growth factor a inhibition in gastric cancer. Gastric Cancer. 18:33–42. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF and Yong WP: A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer. 18:3322018. View Article : Google Scholar : PubMed/NCBI | |
|
Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, Justin TA and Hardcastle JD: Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 56:880–885. 1996.PubMed/NCBI | |
|
Smith AM, Justin T, Michaeli D and Watson SA: Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res. 6:4719–4724. 2000.PubMed/NCBI | |
|
Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE and Caplin ME: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 20:4225–4231. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P and Michaeli D: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol. 30:536–543. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A and Michaeli D: An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study. Cancer. 106:1908–1916. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rocha-Lima CM, de Queiroz Marques Junior E, Bayraktar S, Broome P, Weissman C, Nowacki M, Leslie M and Susnerwala S: A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. Cancer Chemother Pharmacol. 74:479–486. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gastrin 17 vaccine-Aphton, . Anti-gastrin 17 immunogen, G17DT. BioDrugs. 17:223–225. 2003.PubMed/NCBI | |
|
Zhao T, Zhao W, Chen Y, Liu L, Ahokas RA and Sun Y: Differential expression of vascular endothelial growth factor isoforms and receptor subtypes in the infarcted heart. Int J Cardiol. 167:2638–2645. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 65:4939–4946. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M and Tahara H: Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 12:5841–5849. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, et al: Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 41:1297–1304. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ishikawa H, Imano M, Shiraishi O, Yasuda A, Peng YF, Shinkai M, Yasuda T, Imamoto H and Shiozaki H: Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer. 17:173–180. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
ClinicalTrials.gov, . Study of OTSGC-A24 vaccine in advanced gastric cancer. https://clinicaltrials.gov/ct2/show/NCT01227772 | |
|
Valpione S and Campana LG: Immunotherapy for advanced melanoma: Future directions. Immunotherapy. 8:199–209. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Stinchcombe TE: Unmet needs in squamous cell carcinoma of the lung: Potential role for immunotherapy. Med Oncol. 31:9602014. View Article : Google Scholar : PubMed/NCBI | |
|
Dong M, Wang HY, Zhao XX, Chen JN, Zhang YW, Huang Y, Xue L, Li HG, Du H, Wu XY and Shao CK: Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. Hum Pathol. 53:25–34. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shinozaki-Ushiku A, Kunita A and Fukayama M: Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol. 46:1421–1434. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bolm L, Käsmann L, Paysen A, Karapetis C, Rades D, Wellner UF, Keck T, Watson DI, Hummel R and Hussey DJ: Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer. Anticancer Res. 38:3231–3242. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lazăr DC, Avram MF, Romosan I, Cornianu M, Tăban S and Goldis A: Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. World J Gastroenterol. 24:3583–3616. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cui J, Li L, Wang C, Jin H, Yao C, Wang Y, Li D, Tian H, Niu C, Wang G, et al: Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. Cytotherapy. 17:979–988. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Wang C, Xiao H, Niu C, Wu H, Jin H, Yao C, He H, Tian H, Han F, et al: Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer. Cancer Med. 6:45–53. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhandossov O, Kaussova G and Koten A: Combined treatment for gastric cancer: Immunological approach. Turk J Gastroenterol. 29:151–156. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA and Hinrichs CS: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 356:200–205. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al: Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 24:724–730. 2018. View Article : Google Scholar : PubMed/NCBI |
